Student life - Prospect of police interview daunted me, but was my duty.
- Published in:
- Nursing Standard, 2017, v. 31, n. 48, p. 35, doi. 10.7748/ns.31.48.35.s39
- By:
- Publication type:
- Article
Works matching DE "DRUG side effects laws"
Results: 19
1
2
Comment: Statisticians Staying Involved in Benefit-Risk Assessment.
- Published in:
- Statistics in Biopharmaceutical Research, 2016, v. 8, n. 4, p. 426, doi. 10.1080/19466315.2016.1213658
- By:
- Publication type:
- Article
3
The Regulated Dietary Supplement Industry: Myths of an Unregulated Industry Dispelled.
- Published in:
- HerbalGram, 2012, n. 93, p. 42
- By:
- Publication type:
- Article
4
LEGALLY SPEAKING.
- Published in:
- Contemporary OB/GYN, 2015, v. 60, n. 6, p. 56
- By:
- Publication type:
- Article
5
General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2020, v. 45, n. 5, p. 1087, doi. 10.1111/jcpt.13174
- By:
- Publication type:
- Article
6
Pharmacovigilance in China: development and challenges.
- Published in:
- 2018
- By:
- Publication type:
- journal article
7
Black triangle for medicines subject to additional monitoring.
- Published in:
- WHO Drug Information, 2013, v. 27, n. 2, p. 111
- Publication type:
- Article
8
Online publication of suspected side-effect reports.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 273
- Publication type:
- Article
9
Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.
- Published in:
- 2017
- By:
- Publication type:
- journal article
10
Patient Reporting in the EU: Analysis of EudraVigilance Data.
- Published in:
- 2017
- By:
- Publication type:
- journal article
11
Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
- Published in:
- 2016
- By:
- Publication type:
- journal article
12
Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
- Published in:
- 2016
- By:
- Publication type:
- journal article
13
Author's Reply to Borg et al. Comment on: 'EU's New Pharmacovigilance Legislation: Considerations for Biosimilars'.
- Published in:
- Drug Safety, 2014, v. 37, n. 2, p. 125, doi. 10.1007/s40264-013-0130-y
- By:
- Publication type:
- Article
14
Comment On: 'EU's New Pharmacovigilance Legislation: Considerations for Biosimilars'.
- Published in:
- Drug Safety, 2014, v. 37, n. 2, p. 123, doi. 10.1007/s40264-013-0128-5
- By:
- Publication type:
- Article
15
Outcome 6 to 15 Years After Traumatic Brain Injury.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
16
A comparison of hospital episode statistics and traditional methods to identify outcomes in a randomized trial; a sub-study of HEAT-PPCI.
- Published in:
- Journal of Public Health, 2020, v. 42, n. 1, p. 175, doi. 10.1093/pubmed/fdy225
- By:
- Publication type:
- Article
17
The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, p. 33, doi. 10.1007/s00228-013-1486-8
- By:
- Publication type:
- Article
18
Diverse pharmacovigilance jurisdiction—The right way for global drug safety?
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 3, p. 305, doi. 10.1007/s00228-023-03608-y
- By:
- Publication type:
- Article
19
Reporting of deaths during pre-approval clinical trials for advanced HIV-infected populations.
- Published in:
- 2005
- By:
- Publication type:
- journal article